Mon, Sep 1, 2014, 11:05 PM EDT - U.S. Markets closed for Labor Day

Recent

% | $
Quotes you view appear here for quick access.

Pernix Therapeutics Holdings, Inc. Message Board

beavertail_splash 1174 posts  |  Last Activity: Aug 31, 2014 10:23 PM Member since: Apr 13, 2007
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Reply to

    John's Phase I IST Mayo Cohort

    by irishtrader52 Aug 5, 2014 9:45 AM
    beavertail_splash beavertail_splash Aug 31, 2014 10:23 PM Flag

    I'm a belieber Irish. A beaver belieber. ;-3)

  • Reply to

    ASH 2014 question

    by trailblazer1777 Aug 23, 2014 10:38 AM
    beavertail_splash beavertail_splash Aug 31, 2014 9:08 PM Flag

    Sept 1 is but a few hrs away!

  • beavertail_splash beavertail_splash Aug 31, 2014 7:27 PM Flag

    In time GERN will be going after a much wider range of AML's or ANLL's . KITE's c-19 is in phase 1 as is GERN's but neither space has approved first in class drugs yet. I'm not an oncologist but as a beaver I would think these drugs have totally different mechanisms at work on totally different forms of cancer. Combinations of these and other oncology drugs could produce much wider potential applications for treatment. Look at Jakafi many indications as a comfort breakfast cereal topping.
    Imetelstat promising first in class efficacy results in MAYO's MF-1 studies is likely to work in other myeloproliferative disorders (MDS, PV, AML) as well as MF
    With further AML or MDS data Tefferi has yet to present SP could easily catch up to KITE's SP in short order.

  • beavertail_splash beavertail_splash Aug 30, 2014 6:36 PM Flag

    positive results from an ongoing phase I-IIa study on KTE-C19 in patients suffering from aggressive non-Hodgkin's lymphoma(NHL) in the Aug 25, 2014 issue of the American Society of Clinical Oncology's Journal of Clinical Oncology. In the phase I-II study, KTE-C19 achieved 92% overall objective response rate.
    out of 13 patients with advanced B-cell malignancies (including 7 patients with chemotherapy-refractory diffuse large B cell lymphoma (:DLBCL)), 8 achieved complete remission, while 4 achieved partial remission. Additionally, 4 of the 7 chemotherapy-refractory DLBCL patients
    achieved complete remission, while 2 showed partial remission. Among these 4 patients, 3 are showing ongoing complete responses with durations ranging from 9 to 22 months.

    Imetelstat sounds similarly as effective in treating MF (bone marrow fibrosis)
    non-Hodgkin's lymphoma (NHL) originates in the lymph nodes, bone marrow fibrosis (MF) cancer originates in bone marrow. Two different blood cancers requiring two different treatments. Mind you I'd prefer their SP over GERN's right now.

  • Reply to

    Friday's spike in SP

    by beavertail_splash Aug 30, 2014 1:15 PM
    beavertail_splash beavertail_splash Aug 30, 2014 1:23 PM Flag

    looks like 25million GERN shorts scrambling to cover shares?
    25 million x.04= 1mil shares

  • Reply to

    Technical Analysis mixed with fundamental analysis

    by end2war Aug 29, 2014 3:57 PM
    beavertail_splash beavertail_splash Aug 29, 2014 8:50 PM Flag

    GERN shorts buying?

  • Reply to

    As Siga Turns

    by prettycup36 Nov 16, 2007 11:30 AM
    beavertail_splash beavertail_splash Aug 29, 2014 7:45 PM Flag

    never believed this would run for 7 consecutive seasons

  • Reply to

    INCY has to be in the cross hairs

    by mrdtino Aug 25, 2014 10:10 AM
    beavertail_splash beavertail_splash Aug 29, 2014 5:30 PM Flag

    this was their last phase 3
    "The primary hypothesis of the study is that treatment with either once-daily or twice-daily pacritinib results in a greater proportion of patients with thrombocytopenia and myelofibrosis achieving ≥ 35% reduction in spleen volume from baseline to Week 24 than treatment with Best Available Therapy, and a greater proportion of patients achieving a ≥ 50% reduction in total symptom score from baseline to Week 24 as measured by the Myeloproliferative Neoplasm Symptom Assessment Form 2.0" sounds like another version of ruxolitinib.
    "Further study details as provided by CTI BioPharma:
    Primary Outcome Measures:
    Efficacy [ Time Frame: Baseline to Week 24 ] [ Designated as safety issue: No ]
    To compare the efficacy of two dose-schedule arms of pacritinib (pooled once-daily and twice-daily dosing arms) with that of Best Available Therapy in patients with thrombocytopenia and primary myelofibrosis, post-polycythemia vera myelofibrosis, or post-essential thrombocythemia myelofibrosis; the efficacy measure for this analysis is the proportion of patients achieving a ≥ 35% reduction in spleen volume from baseline to week 24 by magnetic resonance imaging (MRI) or computed tomography (CT) and the proportion of patients achieving a ≥ 50% reduction in total symptom score from baseline to Week 24 as measured by the Myeloproliferative Neoplasm Symptom Assessment Form 2.0.
    Secondary Outcome Measures:
    Efficacy [ Time Frame: Baseline to Week 24 ] [ Designated as safety issue: No ]
    To compare the efficacy of once-daily pacritinib with that of Best Available Therapy, as assessed by the proportion of patients achieving a ≥ 35% reduction in spleen volume from baseline to Week 24 by magnetic resonance imaging (MRI) or computed tomography (CT) and the proportion of patients achieving a ≥ 50% reduction in the total symptom score from baseline to Week 24 on the Myeloproliferative Neoplasm Symptom Assessment Form 2.0.
    Efficacy [ Time Frame: Baseline to Week 24 ] [ Designated as safety issue: No

  • Reply to

    Risk vs Reward in GERN

    by beehighve Aug 29, 2014 11:06 AM
    beavertail_splash beavertail_splash Aug 29, 2014 5:18 PM Flag

    Mr Mugoo, if it was such a biggy for CTI BioPharma Corp their SP would have responded with more than a $0.15 pop on the FTD by the FDA. They have a JAK2 inhibitor that pretty well does what Incytes Jakafi does by reducing spleen size but may have fewer serious side effects. E2W is right no biggy.

  • Reply to

    Technical Analysis mixed with fundamental analysis

    by end2war Aug 29, 2014 3:57 PM
    beavertail_splash beavertail_splash Aug 29, 2014 5:02 PM Flag

    well I guess that's better than the choking chicken neck pattern earlier this week.
    Why did ASTY rally today?

  • Reply to

    INCY has to be in the cross hairs

    by mrdtino Aug 25, 2014 10:10 AM
    beavertail_splash beavertail_splash Aug 29, 2014 6:06 AM Flag

    ...what about CTI BioPharma Corp's JAK2 inhibitor pacritinib`s FTD this past August? Any viability there?

  • Reply to

    Recent FDA action on JAK2 competitor in MF

    by end2war Aug 28, 2014 6:49 PM
    beavertail_splash beavertail_splash Aug 29, 2014 5:57 AM Flag

    To tell the truth there wasn't much to see over in CTI BioPharma Corp either when they got the FTD earlier in August. Their SP only moved by $0.15.

  • Reply to

    Recent FDA action on JAK2 competitor in MF

    by end2war Aug 28, 2014 6:49 PM
    beavertail_splash beavertail_splash Aug 28, 2014 9:42 PM Flag

    The Food and Drug Administration (FDA) has developed four distinct and successful approaches to making such drugs available as rapidly as possible: Priority Review, Accelerated Approval, Fast Track Designation, and breakthrough therapy designation. Because each of these approaches implies speed, there can be confusion about the specific meaning of each and the distinctions among them. FTD is NOT the same as BTD. In this case they are going against Jakafi for spleen reductions, not remissions as in Imetelstat.

  • Reply to

    Recent FDA action on JAK2 competitor in MF

    by end2war Aug 28, 2014 6:49 PM
    beavertail_splash beavertail_splash Aug 28, 2014 9:25 PM Flag

    ...remissions are not even considered in their trial design. Another INCYTE-like 'comfort' drug.

  • Reply to

    Recent FDA action on JAK2 competitor in MF

    by end2war Aug 28, 2014 6:49 PM
    beavertail_splash beavertail_splash Aug 28, 2014 9:23 PM Flag

    "The primary hypothesis of the study is that treatment with either once-daily or twice-daily pacritinib results in a greater proportion of patients with thrombocytopenia and myelofibrosis achieving ≥ 35% reduction in spleen volume from baseline to Week 24 than treatment with Best Available Therapy, and a greater proportion of patients achieving a ≥ 50% reduction in total symptom score from baseline to Week 24 as measured by the Myeloproliferative Neoplasm Symptom Assessment Form 2.0" sounds like another version of ruxolitinib.
    "Further study details as provided by CTI BioPharma:
    Primary Outcome Measures:
    Efficacy [ Time Frame: Baseline to Week 24 ] [ Designated as safety issue: No ]
    To compare the efficacy of two dose-schedule arms of pacritinib (pooled once-daily and twice-daily dosing arms) with that of Best Available Therapy in patients with thrombocytopenia and primary myelofibrosis, post-polycythemia vera myelofibrosis, or post-essential thrombocythemia myelofibrosis; the efficacy measure for this analysis is the proportion of patients achieving a ≥ 35% reduction in spleen volume from baseline to week 24 by magnetic resonance imaging (MRI) or computed tomography (CT) and the proportion of patients achieving a ≥ 50% reduction in total symptom score from baseline to Week 24 as measured by the Myeloproliferative Neoplasm Symptom Assessment Form 2.0.
    Secondary Outcome Measures:
    Efficacy [ Time Frame: Baseline to Week 24 ] [ Designated as safety issue: No ]
    To compare the efficacy of once-daily pacritinib with that of Best Available Therapy, as assessed by the proportion of patients achieving a ≥ 35% reduction in spleen volume from baseline to Week 24 by magnetic resonance imaging (MRI) or computed tomography (CT) and the proportion of patients achieving a ≥ 50% reduction in the total symptom score from baseline to Week 24 on the Myeloproliferative Neoplasm Symptom Assessment Form 2.0.
    Efficacy [ Time Frame: Baseline to Week 24 ] [ Designated as safety issue: No

  • beavertail_splash beavertail_splash Aug 27, 2014 12:07 AM Flag

    The only player visible for the last few days was Lizzie Borden. Today vol increased but SP barely held it's own. The trading supports gaming the SP as you have explained but there are few buyers in this increased vol.

  • Reply to

    chrisclub and Occam's Razor: A Modern Day Fable

    by alphapsyche Jul 31, 2008 6:40 PM
    beavertail_splash beavertail_splash Aug 25, 2014 12:07 AM Flag

    ...you've been in this space fur 8 years ...a long time to be underwater.

  • beavertail_splash by beavertail_splash Aug 24, 2014 2:03 PM Flag

    Roche agreed on Sunday to buy InterMune, sells a drug to treat a deadly lung disease, for $8.3 billion. Their only drug pirfenidone treats idiopathic pulmonary fibrosis, a fatal scarring of the lungs.
    This could be GERN down the road. IMETELSTAT has shown to reverse scaring of bone marrow.

  • Reply to

    Website

    by kanderson67 Aug 15, 2014 3:52 PM
    beavertail_splash beavertail_splash Aug 23, 2014 9:19 PM Flag

    Changing the approach to treating cancer
    Developing novel, first-in-class therapeutics
    Working with passion fruit, integrity & true innovation
    Targeting major unmet medical need
    ...all seems on target cept for the passion fruit...Chippy prefers Californian nuts

  • Reply to

    New biz rule

    by sigakingone Aug 23, 2014 7:37 PM
    beavertail_splash beavertail_splash Aug 23, 2014 8:58 PM Flag

    Second guessing the Wilmington Court's decision in applying the law in this case has been a popular board pastime for the past 8 years. Most always guessing the outcome wrong. Been out for the last few years but morbidly curious as to how such a litigation fiasco could have ever taken place. 2 more years will make it a decade.

PTX
8.69+0.26(+3.08%)Aug 29 4:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.
Exelixis, Inc.
NasdaqGSFri, Aug 29, 2014 4:00 PM EDT
Splunk, Inc.
NasdaqGSFri, Aug 29, 2014 4:00 PM EDT